Progress and New Challenges in Combatting the Threat of Antimicrobial Resistance: Perspective From an Infectious Diseases Pharmacist.
作者信息
Shields Ryan K
机构信息
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
出版信息
J Infect Dis. 2024 Feb 14;229(2):303-306. doi: 10.1093/infdis/jiad250.
Abstract
摘要
相似文献
1
Progress and New Challenges in Combatting the Threat of Antimicrobial Resistance: Perspective From an Infectious Diseases Pharmacist.
J Infect Dis. 2024 Feb 14;229(2):303-306. doi: 10.1093/infdis/jiad250.
2
Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists.
Pharmacotherapy. 2023 Apr;43(4):264-278. doi: 10.1002/phar.2781. Epub 2023 Mar 16.
3
Editorial: Antimicrobial resistance in pediatric infectious diseases: antimicrobial resistance, resistance mechanisms and antimicrobial use.
Front Cell Infect Microbiol. 2023 Sep 26;13:1287051. doi: 10.3389/fcimb.2023.1287051. eCollection 2023.
4
[The Role of Pharmacists in AST in Large Hospitals and Their Training].
Yakugaku Zasshi. 2021;141(11):1257-1260. doi: 10.1248/yakushi.21-00107-3.
5
Role of pharmacists in antimicrobial stewardship programmes.
Int J Clin Pharm. 2018 Oct;40(5):948-952. doi: 10.1007/s11096-018-0675-z. Epub 2018 Sep 22.
6
Adding Antimicrobial Stewardship Pharmacists to the Infectious Diseases Compensation Discussion: A More Perfect Union?
Clin Infect Dis. 2024 Jul 19;79(1):271-272. doi: 10.1093/cid/ciad722.
7
Effect of on-call infectious-diseases pharmacists on antibiotic expenditures.
Am J Health Syst Pharm. 2005 Oct 1;62(19):1967-8. doi: 10.2146/ajhp050033.
8
Expanding the scope of the infectious diseases pharmacist in HCT: Beyond antimicrobial stewardship.
Transpl Infect Dis. 2023 Nov;25 Suppl 1:e14094. doi: 10.1111/tid.14094. Epub 2023 Jul 7.
9
Building an Antimicrobial Stewardship Program: Cooperative Roles for Pharmacists, Infectious Diseases Specialists, and Clinical Microbiologists.
Lab Med. 2015 Summer;46(3):e65-71. doi: 10.1309/LMC0SHRJBY0ONHI9.
10
Pharmacist-led antimicrobial stewardship programme in a small hospital without infectious diseases physicians.
Sci Rep. 2022 Jun 9;12(1):9501. doi: 10.1038/s41598-022-13246-6.
引用本文的文献
1
Antibacterial Compounds Isolated from Endophytic Fungi Reported from 2021 to 2024.
Antibiotics (Basel). 2025 Jun 25;14(7):644. doi: 10.3390/antibiotics14070644.
本文引用的文献
1
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11.
2
Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
Open Forum Infect Dis. 2023 Jan 31;10(2):ofad046. doi: 10.1093/ofid/ofad046. eCollection 2023 Feb.
3
Within-Host Genotypic and Phenotypic Diversity of Contemporaneous Carbapenem-Resistant Klebsiella pneumoniae from Blood Cultures of Patients with Bacteremia.
mBio. 2022 Dec 20;13(6):e0290622. doi: 10.1128/mbio.02906-22. Epub 2022 Nov 29.
4
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother. 2022 Dec 23;78(1):252-256. doi: 10.1093/jac/dkac385.
5
Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside.
Clin Microbiol Infect. 2023 Mar;29(3):320-325. doi: 10.1016/j.cmi.2022.10.018. Epub 2022 Oct 18.
6
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
7
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).
Clin Microbiol Infect. 2022 Apr;28(4):521-547. doi: 10.1016/j.cmi.2021.11.025. Epub 2021 Dec 16.
8
Filling the gaps in the global prevalence map of clinical antimicrobial resistance.
Proc Natl Acad Sci U S A. 2021 Jan 5;118(1). doi: 10.1073/pnas.2013515118.
9
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
Clin Infect Dis. 2021 Apr 8;72(7):e169-e183. doi: 10.1093/cid/ciaa1478.
10
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
Zotero 插件